ClinicalTrials.gg
CompletedNCT00513994Updated Apr 11, 2008

MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects

A Phase 1 interventional study of Nitroglycerin in Healthy, sponsored by MediQuest Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-04-11.

Sponsored by MediQuest Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of the study is to measure how much nitroglycerin or its metabolites may be found in the bloodstream when MQX-503 or an FDA approved Nitroglycerin ointment 2% USP is applied to the skin of healthy subjects.

02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
  • Nitroglycerin
  • pharmacokinetics study of nitroglycerin containing treatments
03

In context

Lead sponsor

MediQuest Therapeutics is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers 18 - 70 years of age.
  • Subjects able to give written and comply with study requirements.
  • Subjects willing and able to safely discontinue all current prescription therapies.
  • Subjects who will agree not to participate in other clinical trials.
  • Negative pregnancy test in fertile females and agreement to use effective throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Persons who would be put at risk by discontinuing prescription therapies.
  • Subjects with a known allergy to nitroglycerin.
  • Subjects who have a condition or issue that would adversely affect the application of study medication, study evaluations or the subject's ability to comply with the protocol.
  • Subjects who recently experienced myocardial infarction, uncontrolled congestive heart failure, unstable angina, uncontrolled hypotension or uncontrolled hypertension.
  • Subjects who have participated in a study of an drug within two weeks of visit 1.
  • Subjects who have screening lab values that are out of range or are considered by the investigator.
  • Subjects who have had major abdominal, thoracic, or vascular surgery within 6 months of visit 1.
  • Subjects with non-epithelialized skin lesions or interfering skin conditions at the time of screening in the area where study medication is to be applied.
  • Pregnant or nursing women.
  • Women of who are unwilling to comply with the requirements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Active comparator
    1

    Drug: Nitroglycerin

Interventions

  • MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP

    Also known as: MQX-503, Nitro-Bid

06

What researchers measure

Primary outcomes

  1. The primary objective is the measurement and comparison of the levels of nitroglycerin and its metabolites in the blood of healthy human volunteers after a single topical dose of MQX-503 and a single topical dose of Nitroglycerin Ointment 2%, USP.

    Time frame: 8 hours

Secondary outcomes

  1. A secondary objective is the observation of the volunteers for any adverse events

    Time frame: 2 weeks

07

Study locations

1 site
  • Charles River Clinical Services
    Tacoma, Washington 98418, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2007
First posted
Aug 9, 2007
Start
Aug 2007
CompletionActual
Oct 2007
Last update
Apr 11, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00513994
Lead sponsor
MediQuest Therapeutics
First posted
Aug 9, 2007
Start date
Aug 2007
Completion
Oct 2007
Last update
Apr 11, 2008

Study contacts

Adel Nada, M.D.
principal investigator · Charles River Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion